Single Institutional Experience With Observing 564 Vestibular Schwannomas: Factors Associated With Tumor Growth.
To characterize the risk and predictors of growth during observation of vestibular schwannomas (VS).



Retrospective case series.



Single academic, tertiary care center.



Five hundred sixty-four consecutive VS patients who underwent at least two magnetic resonance imaging (MRI) studies before intervention.



Serial MRI studies.



Tumor growth, defined as a ≥2 mm increase in the maximum tumor diameter between consecutive MRI studies, or between the first and last study.



A total of 1296 patients (1995-2015) with VS were identified. Of those, 564 patients (median age 59.2 years; 53.5% female) were initially observed and underwent multiple MRI studies (median follow-up 22.9 months, interquartile range [IQR] 11.7-42.7). The median maximum tumor diameter at presentation was 1.00 cm (IQR 0.6-1.51 cm). In all, 40.8% of tumors demonstrated growth and 32.1% underwent intervention (21.5% microsurgery, 10.5% radiation) during the surveillance period. Multivariable Cox regression analysis showed that for each tumor, the risk of growth or intervention was significantly increased for larger initial VS diameters (HR = 2.22; 95% CI: 1.90-2.61) and when disequilibrium was a presenting symptom (HR = 1.70; 95% CI: 1.30-2.23). Patient age, sex, aspirin use, and presenting symptoms of asymmetric hearing loss, tinnitus, and vertigo were not associated with tumor growth.



To date, this is the largest series of observed VS reported in the literature. Risk of VS growth is significantly increased among patients who present with larger tumors and who have concomitant disequilibrium.IRB:: 151481.



No cohort with this sample size has assessed vestibular schwannoma growth rates in conjunction with this number of variables.



To characterize vestibular schwannoma growth rates and predictors of growth.
*The Otology Group of Vanderbilt University, Department of Otolaryngology-Head and Neck Surgery†Department of Neurosurgery, Vanderbilt University Medical Center, Nashville, Tennessee.
Jacob B
JB
Hunter
David O
DO
Francis
Brendan P
BP
O'Connell
Edmond K
EK
Kabagambe
Marc L
ML
Bennett
George B
GB
Wanna
Alejandro
A
Rivas
Reid C
RC
Thompson
David S
DS
Haynes
D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009464:Neuroma, Acoustic / Q000473:pathology*; D012189:Retrospective Studies; D012307:Risk Factors
Otol Neurotol. 2014 Feb;35(2):353-7
24448296
Laryngoscope. 1999 May;109(5):736-40
10334223
Otolaryngol Head Neck Surg. 2015 Sep;153(3):440-6
26129740
Am J Otol. 1999 Jul;20(4):495-9
10431892
J Neurosurg. 1958 Nov;15(6):627-41
13599054
J Neurosurg. 2013 Jul;119(1):121-30
23432451
Otol Neurotol. 2014 Aug;35(7):1258-65
24914786
Laryngoscope. 1994 Sep;104(9):1115-9
8072358
Laryngoscope. 2008 Jun;118(6):951-7
18438269
Laryngoscope. 1995 Aug;105(8 Pt 1):795-800
7630289
Otol Neurotol. 2009 Jun;30(4):507-14
19373122
Audiol Neurootol. 2012;17(2):121-5
21968195
Clin Otolaryngol Allied Sci. 1992 Oct;17(5):406-10
1458622
Otol Neurotol. 2003 Jan;24(1):1
12544018
Otol Neurotol. 2006 Aug;27(5):705-12
16868519
Otol Neurotol. 2010 Jul;31(5):807-12
20502379
J Neurosurg. 2009 Apr;110(4):662-9
19099381
Ugeskr Laeger. 2000 Oct 9;162(41):5497-500
11068526
Arch Otolaryngol Head Neck Surg. 2004 Feb;130(2):216-20
14967754
Otol Neurotol. 2002 Jul;23(4):542-9
12170159
Laryngoscope. 2000 Nov;110(11):1843-9
11081597
Otol Neurotol. 2006 Jun;27(4):547-52
16791048
J Neurosurg. 2015 Apr;122(4):833-42
25555165
J Neurosurg. 2005 Jul;103(1):59-63
16121974
Otol Neurotol. 2012 Aug;33(6):1053-8
22710554
Laryngoscope. 2015 Sep;125(9):2163-8
25647714
Otol Neurotol. 2008 Sep;29(6):829-34
18636034
Laryngoscope. 2005 Mar;115(3):450-4
15744156